Aurobindo Pharma Ltd (NSE:AUROPHARMA)
₹ 1185.7 -14.8 (-1.23%) Market Cap: 694.75 Bil Enterprise Value: 695.30 Bil PE Ratio: 21.89 PB Ratio: 2.33 GF Score: 92/100

Full Year 2022 Aurobindo Pharma Ltd Earnings Call Transcript

May 31, 2022 / 03:00AM GMT
Release Date Price: ₹530.8 (+0.50%)
Operator

Ladies and gentlemen, welcome to Quarter 4 FY '22 Earnings Conference Call of Aurobindo Pharma Limited. (Operator Instructions)

I now hand the conference over to Ms. Deepti Thakur. Thank you, and over to you.

Deepti Thakur

Thank you, Aditya. Good morning, and a warm welcome to our fourth quarter FY '22 earnings call. I'm Deepti Thakur from the Investor Relations team. We hope you have received the quarter 4 FY '22 financials in the press release that we were sent out yesterday. These are also available on our website.

I would like to introduce my senior management team today on the call with us, represented by Mr. P.V. Ram Prasad Reddy, Chairman, Aurobindo Pharma USA; Mr. K. Nithyananda Reddy, Vice Chairman and Managing Director of Aurobindo Pharma Limited; Mr. Santhanam Subramanian, CFO; Mr. Yugandhar Puvvala, CEO of Eugia Pharma Specialties Limited; and Dr. Satakarni Makkapati, CEO, Aurobindo's biosimilars, vaccines and peptide businesses.

We will begin the call with summary highlights from the management, followed by an interactive Q

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot